Sustained insulin secretory capacity, defined in the DCCT by a stimulated C-peptide >200 pmol/l at baseline and at least 1 year later, is also associated with lower rates of hypoglycaemia in those treated with intensive insulin therapy [64]. This evidence concerns the gene INS and Hypoglycemia.